Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | APAF1 | O14727 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.35 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11809930 | 0.70 | OPRK1 (0.67) | OPRK1PDE4DHTTKMT2AMEN1 | |
| SCHEMBL30917263 | 0.68 | CRHR1 (0.43) | CYP1A2CYP3A4CYP2C19HTTKMT2A | |
| SCHEMBL9765524 | 0.61 | KDM4E (0.55) | CYP1A2ALDH1A1KDM4E | |
| SCHEMBL1552234 | 0.61 | MAPT (0.60) | OPRK1CYP1A2CYP2C19HTTKMT2A | |
| SCHEMBL31065536 | 0.61 | MAPT (0.60) | OPRK1CYP1A2CYP2C19HTTKMT2A | |
| SCHEMBL6762628 | 0.61 | MAPT (0.60) | OPRK1CYP1A2CYP2C19HTTKMT2A | |
| SCHEMBL29366223 | 0.61 | MAPT (0.60) | OPRK1CYP1A2CYP2C19HTTKMT2A | |
| SCHEMBL1758306 | 0.60 | ALDH1A1 (0.64) | CYP1A2CYP3A4MAPTMAPK1ALDH1A1 | |
| SCHEMBL9212130 | 0.60 | CYP2A6 (0.56) | CYP1A2MAPTALDH1A1KDM4E | |
| SCHEMBL16110543 | 0.60 | OPRK1 (0.65) | OPRK1PDE4DCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7015242-B2 | Methods for treating hyperactive gastrointestinal motility | WYETH (US) | 2006-03-21 | — | — | US | claimed |
| EP-1634594-A1 | Use of 3-substituted oxindole derivatives as KCNQ potassium channel modulators | NeuroSearch A/S (DK) | 2006-03-15 | — | — | EP | claimed |
| EP-1303269-B1 | USE OF 3-SUBSTITUTED OXINDOLE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | NEUROSEARCH AS (DK) | 2005-12-07 | — | — | EP | claimed |
| US-20040029949-A1 | Methods for treating hyperactive gastric motility | WYETH (US) | 2004-02-12 | — | — | US | claimed |
| US-20030181507-A1 | Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators | NEUROSEARCH A/S (DK) | 2003-09-25 | — | — | US | claimed |
| EP-1326597-A2 | METHODS FOR MODULATING BLADDER FUNCTION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-07-16 | — | — | EP | claimed |
| US-20020183395-A1 | Methods for treating hyperactive gastric motility | WYETH | 2002-12-05 | — | — | US | claimed |
| WO-2002080898-A2 | METHODS FOR TREATING HYPERACTIVE GASTRIC MOTILITY | WYETH (US) | 2002-10-17 | — | — | WO | claimed |
| WO-2002032419-A2 | METHODS FOR MODULATING BLADDER FUNCTION | WYETH (US) | 2002-04-25 | — | — | WO | claimed |
| US-6348486-B1 | TREATMENT OF INCONTINENCE | AMERICAN HOME PRODUCTS CORPORATION | 2002-02-19 | — | — | US | claimed |
| EP-0747354-B1 | 3-Substituted oxindole derivatives as potassium channel modulators | BRISTOL MYERS SQUIBB CO (US) | 2000-08-16 | — | — | EP | claimed |
| EP-0747354-A1 | 3-Substituted oxindole derivatives as potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-11 | — | — | EP | claimed |
| US-5565483-A | ADMINISTERING AS THERAPY FOR ISCHEMIA, CONVULSIONS OR ASTHMA | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-15 | — | — | US | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-20060160892-A1 | Methods for treating hyperactive gastric motility | WYETH (US) | 2006-07-20 | — | — | US | disclosed |
| WO-2002000217-A1 | USE OF 3-SUBSTITUTED OXINDOLE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
| EP-0747354-B1 | 3-Substituted oxindole derivatives as potassium channel modulators | BRISTOL MYERS SQUIBB CO (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5602169-A | USEFUL IN REDUCING NEURONAL DAMAGE DURING ISCHEMIC STROKE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-02-11 | — | — | US | disclosed |
| US-5565483-A | ADMINISTERING AS THERAPY FOR ISCHEMIA, CONVULSIONS OR ASTHMA | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029949-A1 | Methods for treating hyperactive gastric motility | KCNQ5, KCNQ3, KCNQ4 | OPRK1 97/4885PDE4D 339/4885CYP1A2 647/4885 |
| US-20020183395-A1 | Methods for treating hyperactive gastric motility | KCNQ5, KCNQ3, KCNQ4 | OPRK1 109/4885PDE4D 280/4885CYP1A2 724/4885 |
| US-20030181507-A1 | Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators | KCNQ1, KCNQ2, KCNQ3 | OPRK1 53/4885PDE4D 1090/4885CYP1A2 1886/4885 |
| US-20060160892-A1 | Methods for treating hyperactive gastric motility | KCNQ5, KCNQ3, KCNQ4 | OPRK1 117/4885PDE4D 271/4885CYP1A2 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.